745 Atlantic Avenue
Oncolinx is developing the next generation of antibody-drug conjugates (ADCs)--powerful, targeted cancer therapies that are more effective and have dramatically fewer side effects than current methods of cancer treatment. These therapies can be targeted to nearly any type of cancer and are rapidly becoming the state-of-the-art in cancer treatment. Drawing on the scientific innovation of the National Cancer Institute, the world's leading biotechs and life sciences companies, Oncolinx is redefining the paradigm of cancer therapy.
Co-Founder and CEO: Sourav Sinha
Co-Founder and COO: Riley Ennis
Co-Founder and CSO: Allen Lin
Business Development Advisor: John Tagliamonte
Lead Inventor, Scientific Advisory Board: Nadya Tarasova, PhD